Placental site trophoblastic tumor

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Placental site trophoblastic tumor
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Abnormal uterine bleeding, amenorrhea, pelvic pain
Complications	Metastasis, infertility
Onset	Reproductive age
Duration	Variable
Types	N/A
Causes	Abnormal proliferation of trophoblastic cells
Risks	Previous molar pregnancy, pregnancy
Diagnosis	Histopathology, imaging studies
Differential diagnosis	Choriocarcinoma, epithelioid trophoblastic tumor
Prevention	N/A
Treatment	Surgery, chemotherapy
Medication	Methotrexate, actinomycin D
Prognosis	Generally good with treatment
Frequency	Rare
Deaths	N/A

Placental Site Trophoblastic Tumor (PSTT) is a rare form of gestational trophoblastic disease (GTD), which arises from the placenta during or after pregnancy. Unlike the more common forms of GTD, such as complete hydatidiform mole and partial hydatidiform mole, PSTT originates specifically from the site where the placenta attaches to the lining of the uterus, known as the implantation site. This tumor is characterized by the abnormal growth of trophoblastic cells, which are cells that normally play a role in the development of the placenta during pregnancy.

Etiology and Pathogenesis

The exact cause of PSTT is not well understood, but it is believed to be related to abnormal proliferation of trophoblastic tissue, which is essential for the development of the placenta. PSTT can occur after a normal pregnancy, a molar pregnancy, an abortion, or even years after the last pregnancy. The tumor develops from the intermediate trophoblasts, which are a type of trophoblastic cell involved in the formation of the placenta.

Clinical Presentation

Patients with PSTT may present with a variety of symptoms, including irregular vaginal bleeding, amenorrhea, or symptoms related to metastasis if the disease has spread beyond the uterus. Unlike other forms of GTD, PSTT typically does not cause markedly elevated levels of the pregnancy hormone beta-human chorionic gonadotropin (β-hCG), making it more challenging to diagnose based on hormone levels alone.

Diagnosis

The diagnosis of PSTT is primarily based on histological examination of tissue obtained from a biopsy or curettage of the uterus. Imaging studies, such as ultrasound and magnetic resonance imaging (MRI), can also be helpful in assessing the extent of the disease and planning treatment. Due to its rarity and the nonspecific nature of its symptoms, PSTT can be difficult to diagnose, and it is often mistaken for other conditions.

Treatment

Treatment for PSTT may involve surgery, chemotherapy, or a combination of both, depending on the stage of the disease and whether it has spread to other parts of the body. Hysterectomy, the surgical removal of the uterus, is often the primary treatment for localized disease. In cases where the disease has spread or in patients who wish to preserve their fertility, chemotherapy may be used.

Prognosis

The prognosis for patients with PSTT varies depending on the stage of the disease at diagnosis and the response to treatment. Early-stage disease that is confined to the uterus has a favorable prognosis with appropriate treatment. However, PSTT can be more aggressive than other forms of GTD, and patients with advanced disease or metastasis may have a poorer outcome.

Epidemiology

PSTT is a very rare condition, accounting for less than 2% of all gestational trophoblastic diseases. It can occur at any age but is most commonly diagnosed in women of reproductive age.